The article reports on the reduction of symptoms and anxiety and improvement in quality of life of patients with non-metastatic breast cancer, colorectal cancer, Hodgkin disease or non-Hodgkin lymphoma due to real-time, 24-hour remote monitoring of chemotherapy adverse effects based on a study at cancer centers in Europe published in "The British Medical Journal" in September 2021.